Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efzofitimod: a novel anti-inflammatory agent for sarcoidosis.
Baughman RP, Niranjan V, Walker G, Burkart C, Paz S, Chong Y, Siefker D, Sun E, Nangle L, Forster S, Muders M, Farver C, Lower E, Shukla S, Culver DA. Baughman RP, et al. Among authors: burkart c. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Mar 28;40(1):e2023011. doi: 10.36141/svdld.v40i1.14396. Sarcoidosis Vasc Diffuse Lung Dis. 2023. PMID: 36975051 Free PMC article.
Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer.
Xu Z, Goel HL, Burkart C, Burman L, Chong YE, Barber AG, Geng Y, Zhai L, Wang M, Kumar A, Menefee A, Polizzi C, Eide L, Rauch K, Rahman J, Hamel K, Fogassy Z, Klopp-Savino S, Paz S, Zhang M, Cubitt A, Nangle LA, Mercurio AM. Xu Z, et al. Among authors: burkart c. Sci Transl Med. 2023 May 3;15(694):eadf1128. doi: 10.1126/scitranslmed.adf1128. Epub 2023 May 3. Sci Transl Med. 2023. PMID: 37134152 Free PMC article.
Development and Characterization of a Novel Neuropilin-2 Antibody for Immunohistochemical Staining of Cancer and Sarcoidosis Tissue Samples.
Förster S, Chong YE, Siefker D, Becker Y, Bao R, Escobedo E, Qing Y, Rauch K, Burman L, Burkart C, Kainz P, Cubitt A, Muders M, Nangle LA. Förster S, et al. Among authors: burkart c. Monoclon Antib Immunodiagn Immunother. 2023 Oct;42(5):157-165. doi: 10.1089/mab.2023.0007. Monoclon Antib Immunodiagn Immunother. 2023. PMID: 37902990
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, Pihusch R, Stauch M, Kaiser F, Kahl C, Karthaus M, Müller C, Burkart C, Reinacher-Schick A, Kasper-Virchow S, Fischer von Weikersthal L, Krammer-Steiner B, Prager GW, Taieb J, Heinemann V. Stintzing S, et al. Among authors: burkart c. J Clin Oncol. 2023 Sep 1;41(25):4143-4153. doi: 10.1200/JCO.22.01420. Epub 2023 Jun 23. J Clin Oncol. 2023. PMID: 37352476 Clinical Trial.
STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling.
Arimoto KI, Löchte S, Stoner SA, Burkart C, Zhang Y, Miyauchi S, Wilmes S, Fan JB, Heinisch JJ, Li Z, Yan M, Pellegrini S, Colland F, Piehler J, Zhang DE. Arimoto KI, et al. Among authors: burkart c. Nat Struct Mol Biol. 2017 Mar;24(3):279-289. doi: 10.1038/nsmb.3378. Epub 2017 Feb 6. Nat Struct Mol Biol. 2017. PMID: 28165510 Free PMC article.
39 results